Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SABS - SAB Biotherapeutics Inc

IEX Last Trade
2.9
0   0%

Share volume: 5,492
Last Updated: Fri 30 Aug 2024 09:57:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%
$2.90
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 10%
Liquidity 53%
Performance 5%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
10.53%
1 Month
8.89%
3 Months
11.36%
6 Months
-30.33%
1 Year
-59.17%
2 Year
-62.78%
Key data
Stock price
$2.90
P/E Ratio 
-0.67
DAY RANGE
N/A - N/A
EPS 
-$5.29
52 WEEK RANGE
$2.16 - $10.50
52 WEEK CHANGE
-$0.60
MARKET CAP 
27.134 M
YIELD 
N/A
SHARES OUTSTANDING 
9.229 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
BETA 
0.08
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$13,576
AVERAGE 30 VOLUME 
$9,025
Company detail
CEO:
Region: US
Website: sabbiotherapeutics.com
Employees: 81
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

sab biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.

Recent news